Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.

Current biology : CB - 12 May 2009

Pfister Edith L, Kennington Lori, Straubhaar Juerg, Wagh Sujata, Liu Wanzhou, DiFiglia Marian, Landwehrmeyer Bernhard, Vonsattel Jean-Paul, Zamore Phillip D, Aronin Neil

Abstract excerpt

Among dominant neurodegenerative disorders, Huntington's disease (HD) is perhaps the best candidate for treatment with small interfering RNAs (siRNAs) [1-9]. Invariably fatal, HD is caused by expansion of a CAG repeat in the Huntingtin gene, creating an extended polyglutamine tract that makes the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Carrier Screening
Share to Genetic Therapy
Share to Huntingtin Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Huntington Disease

Share to Nerve Tissue Proteins

Share to Nuclear Proteins

Share to RNA Interference

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 19361997
DOI: 10.1016/j.cub.2009.03.030
PMCID: PMC2746439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19361997-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.PMID 19361997Read ↗

A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.Semantic proximity Read ↗

Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.Semantic proximity Read ↗

Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.Semantic proximity Read ↗

Using non-coding small RNAs to develop therapies for Huntington's disease.Semantic proximity Read ↗

Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs.Semantic proximity Read ↗

Personalized gene silencing therapeutics for Huntington disease.Semantic proximity Read ↗

Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.Semantic proximity Read ↗

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.Semantic proximity Read ↗

Tailor-made RNAi knockdown against triplet repeat disease-causing alleles.Semantic proximity Read ↗

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment.Semantic proximity Read ↗

Gene targeting techniques for Huntington's disease.Semantic proximity Read ↗

Chemical engineering of therapeutic siRNAs for allele-specific gene silencing <i>in vivo</i> in CNSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.